Physician profile
Aliona Buga
NPI 1588974679
$13,999.57
in general payments reported to CMS, 2019-2025
29 companies · $2,962 in 2025
The $2,962 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,084 · 2022: $1,613 · 2023: $4,342 · 2024: $3,998 · 2025: $2,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,473 · Consulting Fee: $3,435 · Education: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,472.55 |
| Consulting Fee | $3,435.00 |
| Education | $394.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $4,098.78 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $1,591.04 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $1,112.74 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,027.28 | 2021-2025 | Ilumya, Winlevi |
| Incyte Corporation | $1,020.75 | 2021-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $859.59 | 2021-2025 | |
| Lilly USA, LLC | $764.84 | 2021-2025 | Olumiant, Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $480.75 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $456.50 | 2024-2025 | Nemluvio, Aklief |
| Ucb, INC. | $432.57 | 2021-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $345.22 | 2022-2025 | Cabtreo, Siliq, Arazlo |
| Pfizer INC. | $333.87 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $274.55 | 2021-2022 | |
| Leo Pharma INC. | $257.56 | 2022-2025 | Adbry |
| Genzyme Corporation | $215.61 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $152.24 | 2023-2025 | Otezla, Otezla |
| Almirall LLC | $107.72 | 2021-2023 | Seysara |
| Regeneron Healthcare Solutions, INC. | $106.93 | 2021-2025 | Dupixent |
| Revance Therapeutics, INC. | $78.12 | 2025 | Daxxify |
| Dermavant Sciences, INC. | $66.76 | 2023-2024 | Vtama |
| Verrica Pharmaceuticals INC. | $51.24 | 2024 | Ycanth |
| Genentech USA, INC. | $29.18 | 2021 | |
| Epi Health, LLC | $27.17 | 2022 | |
| Mayne Pharma Commercial LLC | $23.07 | 2023 | |
| Organon LLC | $18.46 | 2025 | Vtama |
| Celgene Corporation | $18.27 | 2024 | Sotyktu |
| Botanix Sb INC | $17.56 | 2025 | Sofdra |
| Krystal Biotech INC | $16.08 | 2025 | Vyjuvek |
| Journey Medical Corporation | $15.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliona Buga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.